Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B

Share this
Novo Nordisk


Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B


  • Novo Nordisk signed an agreement to acquire Cardior to enhance and strengthen its Cardiovascular Disease pipeline through Cardior's lead assets including CDR132L for heart failure & preclinical assets CDR348T & CDR641L for hypertrophic cardiomyopathy
  • As per the terms of the agreement, Cardior will receive an aggregate of ~$1.11B as up front, development & commercial milestones
  • CDR132L is currently being evaluated in the P-II (HFrEF) clinical trial in patients suffering from myocardial infarction, the first patient for which was dosed in Jul 2022. Moreover, Novo expects to initiate a 2nd P-II clinical trial for the evaluation of CDR132L in chronic heart failure patients with cardiac hypertrophy

Ref: Novo Nordisk | Image: Novo Nordisk

Related News:- Neomorph and Novo Nordisk Partner to Discover Molecular Glue Degraders for Cardiometabolic and Rare Diseases

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions